Adverse effects
| Adverse effect | During treatment period (0–3 weeks) | After cessation of treatment (3–12 weeks) | ||
|---|---|---|---|---|
| Active (n = 24) | Placebo (n = 25) | Active (n = 24) | Placebo (n = 24) | |
| Values are n (%). | ||||
| CNS, central nervous system. | ||||
| Number of patients with one or more reported adverse effect(s) | 14 (58.3) | 8 (32.0) | 5 (20.8) | 1 (4.2) |
| Gastrointestinal side effects | ||||
| Nausea | 3 (12.5) | 3 (12.0) | 2 (8.3) | |
| Bad taste | 3 (12.5) | 1 (4.2) | ||
| Indigestion | 1 (4.2) | 1 (4.2) | ||
| Diarrhoea | 1 (4.2) | |||
| Constipation | 1 (4.2) | |||
| Weight gain | 1 (4.2) | 1 (4.0) | 1 (4.2) | |
| Increased appetite | 1 (4.0) | |||
| Reduced appetite | 1 (4.0) | |||
| Bloating | 1 (4.2) | |||
| CNS side effects | ||||
| Difficulty sleeping | 3 (12.5) | |||
| Anxious/irritable | 2 (8.3) | |||
| Hyperactive | 2 (8.3) | |||
| Headache | 2 (8.3) | 1 (4.0) | ||
| Dizziness | 1 (4.2) | 3 (12.5) | ||
| Blurred vision | 1 (4.2) | 1 (4.2) | ||
| Cardiovascular side effects | ||||
| Palpitations | 2 (8.3) | |||
| Increased blood pressure | 1 (4.0) | 1 (4.2) | ||
| Facial flushing | 2 (8.3) | 1 (4.0) | 2 (8.3) | |
| Stress fracture foot | 1 (4.2) | |||